EVG Evgen Pharma Plc

TIDMEVG

RNS Number : 3855Y

Evgen Pharma PLC

08 May 2019

Evgen Pharma plc

("Evgen" or the "Company")

Result of GM

and

Completion of Placing

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that at the Company's General Meeting held earlier today, all of the resolutions tabled at the meeting were duly passed.

As a result, the Company is pleased to announce that it expects the remaining 20,275,840 Placing Shares in the Company, to be admitted to trading on the AIM market of the London Stock Exchange on 9 May 2019. This completes the Placing to raise GBP5 million at a price of 15 pence per Ordinary Share, as announced on 17 April 2019.

Total Voting Rights

Following admission of the remaining Placing Shares the total voting rights in the Company will be 132,324,663. The figure of 132,324,663 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the Company's announcement released on 17 April 2019.

For further information please contact:

 
 Evgen Pharma plc 
  Dr Stephen Franklin, CEO                 c/o +44 (0) 20 7466 5000 
  Richard Moulson, CFO 
  www.evgen.com 
 finnCap 
  Geoff Nash, Teddy Whiley (Corporate 
  Finance) 
  Alice Lane, Manasa Patil (ECM) 
  www.finncap.com                              +44 (0) 20 7220 0500 
 WG Partners LLP 
  Nigel Barnes, Claes Spång               +44 (0) 20 3705 9330 
 Buchanan 
  Mark Court, Sophie Wills, Tilly 
  Abraham 
  evgen@buchanan.uk.com                        +44 (0) 20 7466 5000 
 

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

The Group commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ROMLLFFIEDITIIA

(END) Dow Jones Newswires

May 08, 2019 06:29 ET (10:29 GMT)

Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Lug 2023 a Lug 2024